Statins, a group of selective 3-hydroxy-3-methylglutaryl-coenzmye A (HMG-CoA) reductase inhibitors, are widely used in clinical practice as lipid lowering drugs to reduce cardiovascular events. However, after taking statins for some time, some patients may have elevated aminotransferases, hepatosplenomegaly, jaundice, and other clinical liver damaged manifestations, while others may be accompanied with asymptomatic elevated transaminases, increased direct bilirubin level, and prolonged prothrombin time. To a large extent, diagnosis of statin-induced liver injury (SILI) depends on the experience of clinicians, so missed diagnosis and misdiagnosis are common. In this article, we summarized the studies concerning SILI diagnosis to provide references for clinicians to improve diagnostic level.